Whalesbook
📉 The Financial Deep Dive
The Numbers:
Akums Drugs and Pharmaceuticals Limited reported strong top-line growth in Q3 FY26. Revenue stood at ₹1,160 Cr, a 14.8% increase year-on-year (YoY) and a 14.0% sequential jump (QoQ). Adjusted EBITDA mirrored this strength, reaching ₹147 Cr, up 21.0% YoY and 55.4% QoQ. EBITDA margins improved to 12.7% from 12.0% in Q3 FY25 and 9.3% in Q2 FY26, indicating improved operational efficiency at the EBITDA level.
However, the bottom line presented a mixed picture. Adjusted PAT for Q3 FY26 was ₹68 Cr, a marginal 2.1% increase YoY, but significantly lower than the EBITDA growth. PAT margins compressed to 5.7% from 6.5% YoY. QoQ, PAT surged 58.5% from ₹43 Cr, reflecting sequential operational leverage. For the nine months (9M) of FY26, revenue grew 4.5% to ₹3,201 Cr, while EBITDA saw minimal growth of 1.0% to ₹370 Cr. PAT for 9M FY26 declined 8.0% YoY to ₹175 Cr, with margins falling from 6.1% to 5.3%. Exceptional expenses of ₹18 Cr were noted in Q3 FY26 and 9M FY26.
The Quality:
The divergence between EBITDA and PAT growth highlights underlying margin pressures affecting profitability. A significant factor was the 30.4% YoY increase in 'Other Expenses' during Q3 FY26, driven by elevated power and fuel costs, alongside higher professional fees. While EBITDA margins expanded, the PAT margin contraction indicates that these rising operating costs, coupled with softer API prices, are eating into profits before interest and taxes. The investor presentation notably omitted Balance Sheet and Cash Flow data, limiting a comprehensive liquidity and solvency assessment.
The Grill:
Management is navigating several critical challenges. The persistent softness in API prices continues to exert pressure on margins, though stabilization is noted for select molecules. More concerning are the ongoing losses in the Trade Generics and API segments. This necessitates strategic actions like portfolio rationalization and tighter overhead control, suggesting these segments are significant drags on overall profitability. The rise in operating costs, particularly power and fuel, is also a key focus area for cost mitigation strategies. While no auditor concerns were raised, the operational challenges in key segments and rising costs are points of scrutiny for investors.
🚩 Risks & Outlook
Specific Risks:
The primary risks revolve around the sustainability of revenue growth against margin erosion. Continued volatility in API prices, execution risks in large projects, and the ongoing losses in specific business segments pose significant threats to profitability. Escalating operating costs, especially energy and professional services, could further squeeze margins if not managed effectively.
The Forward View:
Akums is strategically positioning itself for future growth through international projects. The European CDMO project is progressing as planned, with EUGMP certification already secured for the oral liquids facility, enabling European formulation supplies. The renewal of Plant 1's EUGMP certification underscores compliance and market access capabilities. The Zambia project is on track for commercial supplies in H1 FY27. Investors will be watching for the impact of portfolio rationalization, cost control measures, and the successful ramp-up of these international ventures to offset domestic segment pressures and drive profitable growth.